Products

PRODUCTS

Nilatinib Maleate


Summary:

It is indicated for adult patients with human epidermal growth factor receptor 2(HER2)-positive early-stage breast cancer after intensive adjuvant therapy with trastuzumab.

File:

NMPA API Registration No.: Y20210001042

Application:

Commercialization

Indications:

Tyrosine kinase inhibitors

Classification:

APIs


Product Details

Product Name
Lainatinib maleate
CAS No.
915942-22-2
Molecular formula
C34H33ClN6O7
molecular weight
673.115
Product Structure
1
 

Related Products

online message

If you have any questions, please leave a message here and leave your contact information. We will reply to you as soon as possible.